CUMYL-TSINACA

A synthetic cannabinoid with a tosylated indazole core, a full CB1 agonist with low affinity, not named in French lists.

Unscheduled

C₂₄H₂₃N₃O₃S

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Data sheet

Names

IUPAC name: 1-(4-methylphenyl)sulfonyl-N-(2-phenylpropan-2-yl)indazole-3-carboxamide

Identifiers

Formula: C₂₄H₂₃N₃O₃S
Molar mass: 433.50 g/mol
PubChem CID: 168322650(new tab)
InChIKey: NZHIGLHQWQLPPC-UHFFFAOYSA-N

Class

Family: Synthetic cannabinoid (SCRA)

Legal status

Status: Unscheduled

See the legal framework

Updated on 13 October 2026

Receptors and activity

CB1Agonist54 out of 100
Ki 292 nM (hCB1, Pulver et coll., 2022) ; EC50 31 µM ; Emax 228 %

Bar length shows the relative strength of the interaction, as an indication.

Subjective signature

Calm: 10 out of 100; Relaxation of body and mind; reduced mental noise without marked drowsiness.
Clarity: 5 out of 100; Sustained attention and clear thinking; functional lucidity, not euphoria.
High: 10 out of 100; Euphoria and sensory intensity; altered perception of time and space.
Appetite: 12 out of 100; Stimulation of hunger and of taste appreciation (the “munchies” effect).
Sleep: 8 out of 100; Sedative effect: aids sleep onset and the continuity of deep sleep.

Editorial estimate, not clinical.

Pharmacology

CUMYL-TSINACA, whose systematic name is 1-(4-methylphenylsulfonyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide, is a synthetic cannabinoid distinguished by a tosyl group on the nitrogen at position 1 of the indazole ring. Described in 2022 by Pulver et al. from products seized in Germany, it behaves as a full agonist at CB1 (Emax of 228 %), but with a very low affinity (Ki of 292 nM) and low functional activity (EC50 of 31 µM). The authors judge its low thermal stability and low potency unfavourable for psychoactive use, which does not prove that it is harmless. No human, pharmacokinetic or toxicological data are published in the sources consulted.

Key sources.

History

Source: A fully synthetic molecule, absent from the cannabis plant. According to Pulver et al. (2022), it belongs to the newer synthetic cannabimimetics, a family that forms the largest category of new psychoactive substances in the European Union. It was identified in illicit products seized in Germany.

Origin (pharmaceutical research → illicit market)

No biosynthetic pathway: a chemically synthesised molecule that exists in no living organism. It belongs to the class of indazole-3-carboxamides, bearing a tosyl group on the N1 nitrogen and a cumyl group on the amide.

Legal framework

European Union: No harmonised European Union control measure was found for this molecule in the sources consulted: its status falls under national legislation. At international level, it does not appear on the INCB Green List (2026 edition, 1971 Convention schedules).
France: Cumyl-TsINACA is not named in the ANSM consolidated list of narcotics (updated 16 February 2026); its structure does not meet the clause covering indazole-3-carboxamide derivatives, which requires on the nitrogen at position 1 a substituent of the type alkyl, haloalkyl, halobenzyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, methyl-oxane, 1-(N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whereas the molecule carries a tosyl group (arylsulfonyl). It is therefore not classified as a narcotic in the texts consulted.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

References

Structured data

SMILES: CC1=CC=C(C=C1)S(=O)(=O)N2C3=CC=CC=C3C(=N2)C(=O)NC(C)(C)C4=CC=CC=C4
InChIKey: NZHIGLHQWQLPPC-UHFFFAOYSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.